Suppr超能文献

血尿患者尿路上皮癌和肾细胞癌的发病率及危险因素的系统评价。

Systematic Review of the Incidence of and Risk Factors for Urothelial Cancers and Renal Cell Carcinoma Among Patients with Haematuria.

机构信息

Department of Urology, Freeman Hospital, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.

Department of Urology, Fundación Instituto Valenciano de Oncología, Valencia, Spain.

出版信息

Eur Urol. 2022 Aug;82(2):182-192. doi: 10.1016/j.eururo.2022.03.027. Epub 2022 Apr 5.

Abstract

CONTEXT

The current impact of haematuria investigations on health care organisations is significant. There is currently no consensus on how to investigate patients with haematuria.

OBJECTIVE

To evaluate the incidence of bladder cancer, upper tract urothelial carcinoma (UTUC), and renal cell carcinoma (RCC) among patients undergoing investigation for haematuria and identify any risk factors for bladder cancer, UTUC, and RCC (BUR).

EVIDENCE ACQUISITION

Medline, Embase, and Cochrane controlled trials databases and ClinicalTrials.gov were searched for all relevant publications from January 1, 2000 to June 2021 according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement. Prospective, retrospective, and cross-sectional studies with a minimum population of 50 patients with haematuria were considered for the review.

EVIDENCE SYNTHESIS

A total of 44 studies were included. The total number of participants was 229701. The pooled incidence rate for urothelial bladder cancer was 17% (95% confidence interval [CI] 14-20%) for visible haematuria (VH) and 3.3% (95% CI 2.45-4.3%) for nonvisible haematuria (NVH). The pooled incidence rate for RCC was 2% (95% CI 1-2%) for VH and 0.58% (95% CI 0.42-0.77%) for NVH. The pooled incidence rate for UTUC was 0.75% (95% CI 0.4-1.2%) for VH and 0.17% (95% CI 0.081-0.299%) for NVH. On sensitivity analysis, the proportions of males (risk ratio [RR] 1.14, 95% CI 1.10-1.17 for VH; 1.54, 95% CI 1.34-1.78 for NVH; p < 0.00001; moderate certainty evidence) and individuals with a smoking history (RR 1.41, 95% CI 1.24-1.61 for VH; 1.53, 95% CI 1.36-1.72 for NVH; p < 0.00001; moderate certainty evidence) appeared to be higher in BUR than in non-BUR groups.

CONCLUSIONS

Male gender and smoking history are risk factors for BUR cancer in haematuria, with bladder cancer being the commonest cancer. The incidence of RCC and UTUC in NVH is low. The review serves as a reference standard for future policy-making on investigation of haematuria by global organisations.

PATIENT SUMMARY

Our review shows that male gender and smoking history are risk factors for cancers of the bladder, kidney, and ureter. The review also provides information on the proportion of patients who have cancer when they have blood in their urine (haematuria) and will allow policy-makers to decide on the most appropriate method for investigating haematuria in patients.

摘要

背景

目前,血尿检查对医疗机构的影响很大。目前,对于血尿患者的检查方法尚未达成共识。

目的

评估因血尿接受检查的患者中膀胱癌、上尿路尿路上皮癌(UTUC)和肾细胞癌(RCC)的发生率,并确定膀胱癌、UTUC 和 RCC(BUR)的任何风险因素。

证据获取

根据系统评价和荟萃分析的首选报告项目,从 2000 年 1 月 1 日至 2021 年 6 月,在 Medline、Embase 和 Cochrane 对照试验数据库以及 ClinicalTrials.gov 中搜索了所有相关出版物。纳入了前瞻性、回顾性和横断面研究,最小人群为 50 例血尿患者。

证据综合

共纳入 44 项研究。共有 229701 名参与者。肉眼血尿(VH)的尿路上皮膀胱癌总发生率为 17%(95%置信区间 [CI] 14-20%),非肉眼血尿(NVH)的总发生率为 3.3%(95% CI 2.45-4.3%)。VH 的 RCC 总发生率为 2%(95% CI 1-2%),NVH 的 RCC 总发生率为 0.58%(95% CI 0.42-0.77%)。VH 的 UTUC 总发生率为 0.75%(95% CI 0.4-1.2%),NVH 的 UTUC 总发生率为 0.17%(95% CI 0.081-0.299%)。在敏感性分析中,男性(风险比 [RR] 1.14,95% CI 1.10-1.17,VH;1.54,95% CI 1.34-1.78,NVH;p<0.00001;中等确定性证据)和有吸烟史的个体(RR 1.41,95% CI 1.24-1.61,VH;1.53,95% CI 1.36-1.72,NVH;p<0.00001;中等确定性证据)在 BUR 组中似乎更高。

结论

男性和吸烟史是血尿中 BUR 癌症的危险因素,膀胱癌是最常见的癌症。NVH 中 RCC 和 UTUC 的发生率较低。该综述为全球组织制定血尿检查政策提供了参考标准。

患者总结

我们的综述表明,男性和吸烟史是膀胱癌、肾脏和输尿管癌症的危险因素。该综述还提供了有关血尿患者癌症比例的信息,这将使决策者能够决定对血尿患者进行最适当的检查方法。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验